Informativeness-Features Question Title * 1. Weighting Informativeness Features (incl calcs) 1 Number of trial sites in entire trial / 2 Multiple sites in a single country trial (Y/N) 3 Tertile of number of sites by domain by phase 4 Multiple countries (Y/N) 5 Number of countries with at least one site 6 Case report form pages-all trial 7 Case report form pages per variable (TBD) 8 Number of visits 9 Duration of trial 10 Tertile of primary duration 11 Duration of follow up (in months) 12 Number of procedures 13 Composite product of tertile of Primary Duration times tertile of Sample Size 14 tertile_of_sample_size by domain by phase 15 two-level binomial lowest tertile of sample size by domain by phase 16 # arms 17 includes analysis of real world data 18 phase-in-domain 19 # of endpoints 20 tertile of number of (co-)primary endpoints by domain by phase 21 Has an SAP 22 Prevalence estimate not discosed or funky 23 Effect estimate not disclosed or funky 24 Uses simulation for sample size 25 # of mentions of the word policy 26 Is a master protocol or a subset or derivative of a master protocol 27 Is part of a platform trial 28 Takes place in a hospital 29 Is an adaptive design 30 Uses model-informed drug development 31 Recency of protocol vs today's date 32 Recent dates in prevalence/burden citations 33 More than 1 drug in the intervention cocktail 34 Patient consortium or trial consortium prominently involved 35 Indicates intention or willingness to make changes at interim Question Title * 2. Weighting Informativeness Features (no calcs) 1 Number of trial sites in entire trial / 2 Multiple sites in a single country trial (Y/N) 3 Multiple countries (Y/N) 4 Number of countries with at least one site 5 Case report form pages-all trial 6 Case report form pages per variable (TBD) 7 Number of visits 8 Duration of trial 9 Duration of follow up (in months) 10 Number of procedures 11 # arms 12 includes analysis of real world data 13 phase-in-domain 14 # of endpoints 15 Has an SAP 16 Prevalence estimate not discosed or funky 17 Effect estimate not disclosed or funky 18 Uses simulation for sample size 19 # of mentions of the word policy 20 Is a master protocol or a subset or derivative of a master protocol 21 Is part of a platform trial 22 Takes place in a hospital 23 Is an adaptive design 24 Uses model-informed drug development 25 Recency of protocol vs today's date 26 Recent dates in prevalence/burden citations 27 More than 1 drug in the intervention cocktail 28 Patient consortium or trial consortium prominently involved 29 Indicates intention or willingness to make changes at interim Done